Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Truscreen Group's Enterprise Value is NZ$7.77 Mil.
Truscreen Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$-2.55 Mil. Therefore, Truscreen Group's EV-to-EBIT ratio for today is -3.05.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Truscreen Group's Enterprise Value is NZ$7.77 Mil.
Truscreen Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$-2.55 Mil. Therefore, Truscreen Group's EV-to-EBITDA ratio for today is -3.05.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Truscreen Group's Enterprise Value is NZ$7.77 Mil.
Truscreen Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$2.11 Mil. Therefore, Truscreen Group's EV-to-Revenue ratio for today is 3.69.
Truscreen Group Enterprise Value Historical Data
The historical data trend for Truscreen Group's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Truscreen Group's Enterprise Value
For the Medical Devices subindustry, Truscreen Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Enterprise Value falls into.
Truscreen Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Truscreen Group's Enterprise Value for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (NZSE:TRU) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Truscreen Group's current Enterprise Value is NZ$7.77 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Truscreen Group's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$-2.55 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Truscreen Group's current Enterprise Value is NZ$7.77 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Truscreen Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$-2.55 Mil.
Truscreen Group's current Enterprise Value is NZ$7.77 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Truscreen Group's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NZ$2.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group Enterprise Value Related Terms
Thank you for viewing the detailed overview of Truscreen Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Truscreen Group Ltd is engaged in providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. The company holds a right to the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. Its product, Truscreen utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The company operates its business in New Zealand, Mexico, China, Russia, Iran, Turkey and others. It has one operating segment, it owns the rights to the Truscreen Cervical Cancer screening device.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NZSE:TRU has been successfully added to your 